Navigation Links
Promising cell protein may play role in infection and dry eye

Plasminogen Activator Inhibitor Type 2 (PAI-2), a protein found in various cell types including the skin, has been discovered in the tissue covering the eye and may have future clinical implications in various pathologies of the ocular surface such as eye infection or dry eye, according to researchers at the University of Pennsylvania and Temple University.

The researchers, led by Mina Massaro-Giordano, M.D., of the University of Pennsylvania's Scheie Eye Institute, and Marcella Macaluso, Ph.D., of the Sbarro Institute for Cancer Research at Temple University (www.shro.org), published their study,

"Cytoplasmic and nuclear interaction between Rb family proteins and PAI-2: a physiological crosstalk in human corneal and conjunctival epithelial cells," in Cell Death and Differentiation (www.nature.com/cdd).

They recently presented their findings at the annual meeting of the Association of Research in Vision and Ophthalmology (ARVO) in Florida, which was attended by over 10,000 researchers.

PAI-2, in either extracellular or secreted form, is a multifunctional protein that plays a role in cell differentiation, in prevention of programmed cell death, in the regulation of cell proliferation, in the inhibition of microbial proteinases and in the protection against stromal degradation.

High levels of the PAI-2 protein are associated with a good prognosis in breast cancer, small cell lung, ovarian cancer, and inhibition of metastasis. PAI-2 also plays a role in inflammation on the surface of the eye.

In their study, the Penn and Temple researchers demonstrate for the first time an interaction between PAI-2 and the tumor suppressing gene Rb2/p130 in the nucleus of the epithelial cells in the cornea and conjunctiva.

According to the researchers, this interaction with Rb2/p130 and chromatin modeling enzymes may affect how PAI-2 is expressed.

"There is a different expression of the protein between the epithelium of the cornea and conjunctiva cells," says Massaro-Giordano, an assistant professor of ophthalmology, cataract and refractive surgery at Scheie. "This may help us understand the molecular mechanisms that dictate the different expression profiles of PAI-2 in human corneal and conjunctival epithelial cells."


'"/>

Source:Temple University


Related biology news :

1. Another Look Finds Promising Proteomics Test is Not Biologically Plausible
2. Promising new West Nile therapy cures disease in mice
3. Promising therapies for haemophilia & heart disease
4. New, automated tool successfully classifies and relates proteins in unprecedented way
5. New binding target for oncogenic viral protein
6. Controversial drug shown to act on brain protein to cut alcohol use
7. Timing is everything: First step in protein building revealed
8. UWs Rosetta software to unlock secrets of many human proteins
9. Researchers find how protein allows insects to detect and respond to pheromones
10. Signaling protein builds bigger, better bones in mice
11. Ancient olfaction protein is shared by many bugs, offering new pest control target
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/11/2017)... MOINES, Iowa , Jan. 11, 2017 ... industry first with the release of its patent-pending calibration ... quickly and reliably perform calibrations, securely upload data logs ... flexibility for the customer. "Fighting drunk driving ... only for the public at large, but also for ...
(Date:1/6/2017)... , Jan. 5, 2017  SomaLogic announced today ... Life Alliance" established by iCarbonX, the ... build a "Global Digital Health Ecosystem that can ... combination of individual,s biological, behavioral and psychological data, ... between the companies, SomaLogic will provide proteomics data ...
(Date:1/4/2017)... Jan. 4, 2017  CES 2017 – Valencell ... technology, today announced the launch of two new ... the highly-accurate biometric sensor modules that incorporate the ... experience and expertise. The two new designs include ... for hearables, and Benchmark BW2.0, a 2-LED version ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... England , January 23, 2017 ... today announces completion of its Series D financing, raising $35 ... one new investor, Wondfo Biotech. ... Development of the Atlas Genetics io® ... the Chlamydia trachomatis (CT) test announced in February 2016.  This ...
(Date:1/21/2017)... ... January 20, 2017 , ... G&L ... the healthcare industry ( http://www.gandlscientific.com ), has announced the opening of new offices ... and scientific consultants and contractors. This is the latest step in G&L’s expansion ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... January 20, 2017 http://www.Financialbuzz.com ... one of leading causes of death worldwide. There were ... number of cancer related deaths increased gradually over time, ... incidence rate of various cancers continues to drive demand ... report by Global Market Insights, Inc. cancer biological therapy ...
Breaking Biology Technology: